GENZYME CORP
DEFA14A, 1995-05-10
PHARMACEUTICAL PREPARATIONS
Previous: HILLS BANCORPORATION, 10-Q, 1995-05-10
Next: BANKERS FIRST CORP, 10-Q, 1995-05-10



<PAGE>   1

14a-6(b) Soliciting Material for the Annual Meeting of Stockholders on May 18,
1995.


May 10, 1995


Dear:


        One of the questions before the shareholders of Genzyme Corporation is
a request to increase the number of Genzyme General Division shares available
for the granting of stock options. I urge you to support this proposal.

        This is the first Annual Meeting since Genzyme created a second class
of stock, Genzyme Tissue Repair in the fall of 1994. All shareholders of
Genzyme Corporation, those with an ownership position in Genzyme General and
those with a position in Genzyme Tissue Repair, generally vote on all issues
brought before the shareholders. Each share of Genzyme General has one vote and
each share of Genzyme Tissue Repair has .29 votes. The relative voting power of
each stock was set when the Tissue Repair stock was established and will be
revalued every second year based upon the relative trading prices of the two
stocks.

        In determining earnings per share, a calculation of earnings per share
is made of the General Division and of the Tissue Repair Division. There is no
calculation made of Genzyme Corporation as there is no common stock         --
representing an ownership interest in the Corporation as a whole. Consequently,
you must not focus on aggregate shares and options outstanding but rather those
shares and options for each class of stock, independently. Institutional
Shareholder Services, Inc. has erroneously aggregated all classes of stock in 
computing potential dilution.

        I refer you to page 18 of the Company's 1995 proxy statement which
articulates the Company's policy on granting stock options to all its employees
and how we have administered an equitable plan across all levels in the
Company.

        I also call your attention to question 4 which prohibits the granting
of nonstatutory options at less than fair market value.

        Genzyme has successfully used stock options to build a diversified,
rapidly growing and successful biotechnology company. Competition for highly
motivated, intelligent and well educated employees is significant. Our success
to date in hiring and retaining these employees is in no small part due to our
broad based equity plan.

        Your favorable vote on Question 2 is requested.


Sincerely,


David J. McLachlan
Senior Vice President




© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission